Table 1.
List of part of ongoing clinical trials of OVs on Clinical trials.gov.
| Viral backbone | Oncolytic virus | Gene modification | Combination | Indication | Status/phase | ClinicalTrial.gov identifier |
|---|---|---|---|---|---|---|
| Adenovirus | DNX-2401 | Δ24-RGD insertion | / | Glioblastoma | Recruiting; phase 1 | NCT03896568 |
| Adenovirus | ORCA-010 | Δ24-RGD insertion; insertion of T1 mutation in E3/19K gene | / | Prostate cancer | Recruiting; phase 1/2a | NCT04097002 |
| Adenovirus | LOAd703 | Encoding for TMZ-CD40L and 4-1BBL | Gemcitabine+nabpaclitaxel+/-atezolizumab | Pancreatic cancer | Recruiting; phase 1/2a | NCT02705196 |
| Vesicular stomatitis virus | VSV-IFNβ-NIS | Encoding for interferon β (IFNβ) and the sodium iodide symporter (NIS) | Pembrolizumab | Non-small cell lung cancer; head and neck squamous cell carcinoma | Recruiting; phase 1 | NCT03647163 |
| Vesicular stomatitis virus | VSV-IFNβ-NIS | Encoding for interferon β (IFNβ) and the sodium iodide symporter (NIS) | Cemiplimab | Melanoma; hepatocellular carcinoma; non small cell lung cancer; endometrial cancer | Recruiting; phase 2 | NCT04291105 |
| Herpes simplex virus | G207 | Deletion of both γ134.5 loci; insertional inactivation of UL39 | / | Cerebellar brain tumor | Recruiting; phase 1 | NCT03911388 |
| Herpes simplex virus | OH2 | Encoding for human granulocyte macrophage colony-stimulating factor (GM-CSF) | / | Pancreatic cancer | Recruiting; phase1b/2 | NCT04637698 |
| Herpes simplex virus | ONCR-177 | Encoding for IL-2, CCL4, FLT3L, antagonists CTLA-4 and PD-1 | Pembrolizumab | Solid tumor | Recruiting; phase 1 | NCT04348916 |
| Newcastle disease virus | MEDI5395 | Encoding for GM-CSF | Durvalumab | Solid tumor | Recruiting; phase 1 | NCT03889275 |
| Reovirus | Pelareorep | Wild-type variant | Paclitaxel+avelumab | Metastatic breast cancer | Recruiting; phase 2 | NCT04215146 |
| Reovirus | Pelareorep | Wild-type variant | Pembrolizumab | Pancreatic cancer | Active, not recruiting; phase 2 | NCT03723915 |
| Measles virus | MV-s-NAP | Expressing the helicobacter pylori neutrophil-activating protein | / | Metastatic breast cancer | Recruiting; phase 1 | NCT04521764 |
| Measles virus | MV-NIS | Expressing the sodium-iodide symporter (NIS) | / | Medulloblastoma; atypical teratoid rhabdoid tumor | Recruiting; phase 1 | NCT02962167 |
| Poliovirus | PVSRIPO | Containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 | / | Invasive breast cancer | Recruiting; phase 1 | NCT03564782 |
| Poliovirus | PVSRIPO | Containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 | / | Recurrent malignant glioma | Recruiting; phase 1b | NCT03043391 |
| Vaccinia virus | T601 | Deletion of genes of thymidine kinase and ribonucleotide reductase; insertion of FCU1 gene | Flucytosine | Malignant solid tumors | Recruiting; phase 1/2a | NCT04226066 |
| Vaccinia virus | TBio-6517 | Expressing an anti-CTLA-4 antibody, Flt3 and IL-12 | Pembrolizumab | Advanced solid tumors | Recruiting; phase 1/2a | NCT04301011 |
| Coxsackievirus | V937 | Wild-type variant | Pembrolizumab | Advanced/metastatic solid tumors | Recruiting; phase1b/2 | NCT04521621 |